Invitation to conference call and webcast

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) is conducting an analyst and investor conference call/webcast today, 9th January 2017, at 15.00 CET, to present further financial aspects of the acquired oncology programs from TetraLogic Pharmaceuticals Corporation, including the clinical stage compounds remetinostat and birinapant.

Niklas Prager CEO, Ola Burmark CFO and Richard Bethell CSO will be presenting and will be available for questions.

To join the conference call, please dial:
Sweden +46 (0)8 566 426 62
Europe +44(0)20 300 898 02
USA +1 855 753 22 35  

The webcast can be accessed on the website: www.medivir.com

For further information, please contact:
Niklas Prager, CEO and President Medivir AB, +46 8 407 6430
Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

About Medivir
Medivir is a research based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir’s class B share is listed on the Nasdaq Stockholm Mid Cap List.

Tags:

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe

Documents & Links